This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer's Chantix Linked to Heart Problems

NEW YORK ( TheStreet) -- A Pfizer (PFE - Get Report) stop-smoking drug increases the risk of cardiovascular events such as heart attacks, according to researchers who analyzed multiple trials involving the drug.

After reviewing 14 trials of the drug Chantix (varenicline), the researchers wrote that the drug's use was associated with a 72% risk of "serious adverse cardiovascular events."

The trials involved 8,216 participants and ranged in duration from seven to 52 weeks.

The researchers concluded that their analysis raises safety concerns about the use of the drug by tobacco users.

> > Bull or Bear? Vote in Our Poll

They published their findings in the Canadian Medical Association Journal.

The Food and Drug Administration recently placed a warning in the information that comes with the drug about additional cardiovascular risks for people already suffering from heart disease, according to a report by the BBC.

A Pfizer representative said the company "disagreed with the interpretation of the data" used by the researchers," the BBC report said.

Shares of Pfizer closed Friday up 15 cents at $20.75. U.S. stock markets were closed Monday in observance of Independence Day.
This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
PFE $32.66 0.00%
AAPL $113.29 0.00%
FB $91.01 0.00%
GOOG $630.38 0.00%
TSLA $248.48 0.00%

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs